Acadia Pharmaceuticals saw the highest growth of 0.49% in patent filings and 0.19% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.39% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Acadia Pharmaceuticals’s patent filings and grants. Buy the databook here.
Acadia Pharmaceuticals has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 17% grants. The United States(US), Denmark(DK), European Patent Office(EPO), and Canada(CA) patent Office are among the top ten patent offices where Acadia Pharmaceuticals is filings its patents. Among the top granted patent authorities, Acadia Pharmaceuticals has 17% of its grants in United States(US), 17% in Canada(CA) and 17% in Finland(FI).
Roche and Johnson & Johnson could be the strongest competitors for Acadia Pharmaceuticals
Patents related to rare diseases and climate change lead Acadia Pharmaceuticals's portfolio
Acadia Pharmaceuticals has the highest number of patents in rare diseases followed by, climate change. For rare diseases, nearly 100% of patents were filed and 50% of patents were granted in Q2 2024.
Prader-willi syndrome (pws) related patents lead Acadia Pharmaceuticals portfolio followed by petrochemicals, and bipolar disorder (manic depression)
Acadia Pharmaceuticals has highest number of patents in prader-willi syndrome (pws) followed by petrochemicals, bipolar disorder (manic depression), diabetes, and gastrointestinal.
For comprehensive analysis of Acadia Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.